Suppr超能文献

米兰和 UCSF 标准范围内的移植性肝细胞癌患者的肝切除术。

Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria.

机构信息

Department of Surgery, Hepatobiliary and Surgical Oncology Unit, University of New South Wales, St George Hospital, Kogarah, Sydney, Australia.

出版信息

Am J Clin Oncol. 2012 Apr;35(2):141-5. doi: 10.1097/COC.0b013e318209ab7d.

Abstract

BACKGROUND

Liver transplantation is believed to be the best treatment option for selected patients with hepatocellular carcinoma (HCC). However, the shortage of organs and the risk of tumor progression while on the waiting list has hampered this effective treatment modality from being routinely offered. Hence, the second option of hepatic resection must be considered. The aim of this study is to report the results of hepatic resection in transplantable patients.

METHODS

From 1991 to 2009, 97 patients underwent liver resection for HCC. Thirty patients (31%) met transplant criteria [(Milan/University of California San Francisco (UCSF) Liver Transplant Criteria]. Outcomes after hepatic resection were evaluated with disease-free survival (DFS) and overall survival as the endpoints by stratification of transplant eligibility.

RESULTS

There were 30 patients within the UCSF transplant criteria and 16 patients within the Milan transplant criteria. By using either transplant criteria, patients survived an actuarial median survival of 102 months. Patients selected based on the Milan criteria had a median DFS of 55 months and patients selected based on the UCSF criteria had a median DFS of 42 months. Patients who were Child Pugh B (UCSF criteria P<0.001) and with cirrhosis had a poorer outcome after hepatic resection (UCSF criteria P=0.011, Milan criteria P=0.002).

CONCLUSIONS

Long-term DFS and overall survival may be achieved through hepatic resection for transplantable HCC. This is an effective option and may be regarded as a first-line treatment option. Patients with Child Pugh B or are cirrhotics may benefit more from a transplantation than a resection.

摘要

背景

肝移植被认为是治疗肝细胞癌(HCC)的最佳选择。然而,由于器官短缺以及在等待名单上肿瘤进展的风险,这种有效的治疗方法无法常规提供。因此,必须考虑第二种选择,即肝切除术。本研究旨在报告可移植患者行肝切除术的结果。

方法

1991 年至 2009 年,97 例 HCC 患者接受了肝切除术。30 例(31%)符合移植标准[米兰/加利福尼亚大学旧金山分校(UCSF)肝移植标准]。通过分层移植资格,以无病生存(DFS)和总生存为终点,评估肝切除术后的结果。

结果

有 30 例符合 UCSF 移植标准,16 例符合米兰移植标准。无论采用哪种移植标准,患者的生存时间均为 102 个月的估计中位数。根据米兰标准选择的患者的中位 DFS 为 55 个月,根据 UCSF 标准选择的患者的中位 DFS 为 42 个月。根据 UCSF 标准,Child-Pugh B 级(UCSF 标准 P<0.001)和肝硬化患者肝切除术后的结局较差(UCSF 标准 P=0.011,米兰标准 P=0.002)。

结论

通过肝切除术治疗可移植 HCC 可获得长期 DFS 和总生存。这是一种有效的选择,可被视为一线治疗选择。Child-Pugh B 级或肝硬化患者可能从移植中获益更多,而非切除。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验